Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

National health plan

FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List

The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the…
January 19, 2023

Recent Articles

January 19, 2023

FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. January 2, 2025
    NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
    0013.HK HCM.US
  3. December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  4. December 24, 2024
    BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing
    6855.HK
  5. November 21, 2024
    PegBio aims to bulk up its finances to deliver weight-loss drugs
  6. January 24, 2025
    BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million
    6855.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.